New PET scan agent spots prostate cancer missed by standard tests
NCT ID NCT05407311
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 study tested a new radioactive imaging agent called 64Cu-SAR-BBN in 53 men with prostate cancer that had returned after treatment but was not visible on standard PSMA PET scans. The goal was to see if this agent could safely and accurately detect where the cancer had recurred. Results could help doctors find hidden cancer spots and choose better treatments.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- 64Cu-SAR-BBN (a radioactive imaging agent)
- What this could lead to
- If successful, this could provide a new way to detect prostate cancer recurrence in patients who don't show up on standard PSMA scans, helping guide treatment decisions.
- What could go wrong
- This is a small, early-phase study (53 participants) focused on imaging accuracy, not treatment. The agent may not detect all recurrences, and results need confirmation in larger trials.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BIOCHEMICAL RECURRENCE OF MALIGNANT NEOPLASM OF PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Bamf Health, Inc
Grand Rapids, Michigan, 49503, United States
-
Biogenix Molecular
Miami, Florida, 33165, United States
-
Carolina Urologic Research Center
Myrtle Beach, South Carolina, 29572, United States
-
GU Research Network
Omaha, Nebraska, 68130, United States
-
St Louis University Hospital
St Louis, Missouri, 63104, United States
-
Stanford University
Stanford, California, 94305, United States
-
Tower Urology
Los Angeles, California, 90048, United States
-
Urology San Antonio
San Antonio, Texas, 78258, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.